Literature DB >> 758787

Reliability of theophylline clearance in determining chronic oral dosage regimens.

M L Slotfeldt, C E Johnson, G Grambau, J G Weg.   

Abstract

Predicted and approximated mean serum theophylline concentrations were compared to assess the feasibility of using theophylline clearance, calculated from the intravenous steady-state serum theophylline concentration, to determine appropriate oral dosage requirements. Ten patients with reversible airway disease (age 7 to 64 years) received theophylline (as Aminophylline USP) by constant i.v. infusion. Theophylline clearance was calculated for each patient from steady-state serum theophylline concentrations determined from blood samples obtained after a least 48 hours of constant theophylline infusion. Aminophylline USP tablets were then adminstered orally. Blood levels measured at peak and trough times following oral theophylline administration were used to calculate an approximate mean serum theophylline concentration. The relationship between predicted and approximated mean serum theophylline concentrations was calculated and analyzed by orthogonal least square regression line. Serum theophylline concentrations ranged from 5.1 microgram/ml to 20.1 microgram/ml, and clearances ranged from 0.03 liter/kg/hr to 0.09 liter/kg/hr. During oral therapy, the maximum concentration ranged from 10.4 microgram/ml to 23.8 microgram/ml, while the minimum ranged from 6.5 microgram/ml to 15.2 microgram/ml. The difference between predicted and approximated mean serum concentrations was within +/-1.6 micrograms/ml in all cases. The study indicates that the theophylline clearance calculated from i.v. infusion data can be used to determine appropriate oral dosage requirements.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 758787

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  7 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Relationship of bioelectrical impedance to pharmacokinetic parameters of theophylline in healthy males.

Authors:  B J Zarowitz; E Peterson; J Popovich
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

3.  Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.

Authors:  M Parent; M St-Laurent; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 4.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 5.  An updated comparison of drug dosing methods. Part II: Theophylline.

Authors:  S M Erdman; K A Rodvold; R D Pryka
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

6.  Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose.

Authors:  Y Horai; T Ishizaki; T Sasaki; M Watanabe; J Kabe
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  A comparison of the accuracy of a least squares regression, a Bayesian, Chiou's and the steady-state clearance method of individualising theophylline dosage.

Authors:  S F Hurley; J J McNeil
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.